ライフサイエンスコーパス: releasing hormone

1 achineries to liberate this key hypothalamic releasing hormone.

2 ropin-releasing hormone (CRH) or thyrotropin-releasing hormone.

3 eus was identified as containing thyrotropin-releasing hormone.

4 ynorphin, somatostatin, and/or corticotropin releasing hormone.

5 rive the pulsatile secretion of gonadotropin-releasing hormone.

6 n episodic, excitatory drive to gonadotropin-releasing hormone 1 (GnRH) neurons, the synaptic mechani

7 transcriptionally regulated by gonadotropin-releasing hormone 1 (GNRH).

8 During mammalian development, gonadotropin-releasing-hormone-1 neurons (GnRH-1ns) migrate from the

9 CRH (corticotropin-releasing hormone), a peptide released from hippocampal

10 udes suppression of hypothalamic thyrotropin-releasing hormone, accounting for persistently reduced s

11 sex hormone fluctuation using a gonadotropin-releasing hormone agonist (GnRHa) and evaluated if emerg

12 ly that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemot

13 astration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy.

14 es encapsulating a model luteinizing hormone-releasing hormone agonist (LHRHa)-based peptide, leuprol

15 Luteinizing hormone-releasing hormone agonist (LHRHa; leuprolide acetate) do

16 d androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide.

17 rchiectomy or receipt of luteinising hormone-releasing hormone agonist or antagonist therapy started

18 Gonadotropin-releasing hormone agonist therapy is associated with hig

19 rogression and continued luteinising hormone-releasing hormone agonist therapy.

20 o cixutumumab added to a luteinizing hormone-releasing hormone agonist with bicalutamide versus AD al

21 every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT)

22 ndomly assigned 2:1 to a luteinizing hormone-releasing hormone agonist, bicalutamide and bevacizumab

23 rian suppression induced by the gonadotropin-releasing hormone agonist, leuprolide acetate; leuprolid

24 authors examined the effects of gonadotropin-releasing hormone agonist-induced ovarian suppression on

25 n to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhi

26 as achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or

27 Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the st

28 Gonadotropin-releasing hormone agonists (GnRHa) have been suggested a

29 Puberty suppression by gonadotropin-releasing hormone agonists (GnRHa), such as leuprolide,

30 4.04 [95% CI, 1.88-8.69]), and gonadotropin-releasing hormone agonists (OR, 1.93 [95% CI, 1.20-3.10]

31 rivation therapy in the form of gonadotropin-releasing hormone agonists and newer antagonists, examin

32 Gonadotropin-releasing hormone agonists given with chemotherapy was a

33 androgen blockade consisting of gonadotropin-releasing hormone agonists with oral antiandrogens (OR,

34 of 6 mutually exclusive groups: gonadotropin-releasing hormone agonists, oral antiandrogens, combined

35 Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate can

36 Luteinizing hormone releasing hormone analog (LHRHa, des Gly10, [D-Ala6] eth

37 Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral

38 5], gonadotropins [n = 57 136], gonadotropin-releasing hormone analogs [n = 38 653], human chorionic

39 ter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for

40 Gonadotropin-releasing hormone analogue triptorelin, bilateral oophor

41 intrauterine system (LNG-IUD), gonadotropin-releasing hormone analogues (GnRHa; nafarelin, leuprolid

42 er the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy

43 Gonadotropin-releasing hormone analogues and laparoscopic ablation or

44 (castration via orchiectomy or gonadotropin-releasing hormone analogues) suppresses circulating test

45 Gonadotropin-releasing hormone analogues, danazol, and depot progesta

46 corticotropin-releasing factor, thyrotropin-releasing hormone and calcitonin gene-related peptide) i

47 ticotrophin-releasing hormone or thyrotropin-releasing hormone and do not express arginine vasopressi

48 eptors, their regulator Fkbp5, corticotropin releasing hormone and its receptor, oxytocin and its rec

49 ediated by reduced secretion of gonadotropin-releasing hormone and our results support the involvemen

50 ed hypothalamic expression of corticotrophin-releasing hormone and oxytocin, neuropeptides known to c

51 (GH) secretion is primarily controlled by GH-releasing hormone and somatostatin neurons.

52 mber of DMV neurones excited by thyrotrophin-releasing hormone and the gastric motility response to D

53 the endogenous natural ligand, gonadotropin releasing hormone, and an agonist that is specific for t

54 tocin, vasopressin, enkephalin, thyrothropin-releasing hormone, and corticotropin-releasing factor im

55 .e., C-reactive protein (CRP), corticotropin-releasing hormone, and cytokines) were compared among te

56 prohormone processing of proinsulin, pro-GH-releasing hormone, and proghrelin in association with re

57 mitters such as glutamate, GABA, thyrotropin releasing hormone, and substance P encoded by the Tachyk

58 tide markers (cholecystokinin, corticotropin-releasing hormone, and tachykinin 1) label sleep-promoti

59 Gonadotropin releasing hormone antagonism successfully reduced circul

60 ive hormone production using a gonadotrophin-releasing hormone antagonist (GnRHant) for 10 days, with

61 Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversi

62 g hormone and administration of gonadotropin-releasing hormone antagonist to prevent premature ovulat

63 edicine report on an oral lutenizing-hormone-releasing hormone antagonist with superior endocrine and

64 nd safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of

65 stage in both immature mice and gonadotropin releasing hormone antagonist-treated adult mice.

66 n T through administration of a gonadotropin releasing hormone antagonist.

67 luster express a reporter for corticotrophin-releasing hormone (Bar(CRH) ).

68 utamatergic neurons expressing corticotropin releasing hormone (Bar(Crh/Vglut2)) are implicated in bl

69 rs28365143 variant within the corticotropin-releasing hormone binding protein (CRHBP) gene predicted

70 We demonstrate that corticotropin-releasing-hormone-binding protein (CRHBP), an antagonist

71 creased somewhat by exposure to gonadotropin-releasing hormone but are not necessarily linked to Cga

72 Using a corticotropin releasing hormone-cre driver X tdTomato reporter mouse,

73 hat encode the stress hormones corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone.

74 o hypothalamic secretagogues, corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) t

75 o hypothalamic secretagogues, corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) t

76 script (CART), oxytocin (OX), corticotrophin releasing hormone (CRH) and calcitonin gene-related pept

77 and stress molecules including corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted i

78 ormone (ACTH) by hypothalamic corticotrophin-releasing hormone (CRH) and then stimulation of the adre

79 detection of the neuropeptide Corticotropin Releasing Hormone (CRH) based on the immobilization of h

80 sh with transgenically labeled corticotropin-releasing hormone (CRH) cells, which represent a major r

81 l-genetic approaches to reduce corticotropin-releasing hormone (Crh) expression in the central nucleu

82 the production and release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus

83 he suppression of hypothalamic corticotropin-releasing hormone (CRH) gene expression and potently enh

84 ion between macroautophagy and Corticotropin Releasing Hormone (Crh) in the gut.

85 cluster of neurons expressing corticotropin-releasing hormone (Crh) in the pontine micturition cente

86 Corticotropin-releasing hormone (CRH) is a central integrator in the b

87 Corticotropin-releasing hormone (CRH) is a major regulator of the hypo

88 Corticotropin-releasing hormone (CRH) is an essential, evolutionarily-

89 Corticotropin releasing hormone (CRH) is disrupted in individuals with

90 in-releasing hormone (TRH) and corticotropin-releasing hormone (CRH) neurons expressed GH-induced pST

91 lasticity in stress-responsive corticotropin-releasing hormone (CRH) neurons in female mice.

92 ity at glutamate synapses onto corticotropin-releasing hormone (CRH) neurons in the paraventricular n

93 xiety-related behaviours, and corticotrophin releasing hormone (crh) neurons, key regulators of the s

94 ansmit signals to hypothalamic corticotropin-releasing hormone (CRH) neurons, which control stress ho

95 atory synaptic strength in PVN corticotropin-releasing hormone (CRH) neurons, with GLP-1R activation

96 actions of corticosterone and corticotropin-releasing hormone (CRH) on synaptic physiology and dendr

97 xytocin, arginine vasopressin, corticotropin-releasing hormone (CRH) or thyrotropin-releasing hormone

98 corticosterone and hippocampal corticotropin-releasing hormone (CRH) permeate memory-forming hippocam

99 u receptor 2 and signaling via corticotropin releasing hormone (Crh) receptor 1.

100 adigm posits that hypothalamic corticotropin-releasing hormone (CRH) regulates neuroendocrine functio

101 Corticotropin-releasing hormone (CRH) released from the paraventricula

102 The corticotrophin-releasing hormone (CRH) system integrates the stress res

103 n, increased activation of the corticotropin-releasing hormone (CRH) system within the extended amygd

104 (WM) deficits; changes to the corticotropin-releasing hormone (CRH) system; and structural, function

105 rations and gene expression of corticotropin-releasing hormone (CRH) were not affected by oxazepam.

106 Activation of amygdalar corticotropin-releasing hormone (CRH)+ neurons abolished the increase

107 ive preclinical data implicate corticotropin-releasing hormone (CRH), acting through its CRH1 recepto

108 Although corticotropin-releasing hormone (CRH), produced by parvocellular neuro

109 ected and processed to measure corticotropin-releasing hormone (CRH), urocortin (Ucn), beta-endorphin

110 stimulating the expression of corticotropin-releasing hormone (CRH), urocortin, proopiomelanocortin

111 4), a homolog of the mammalian corticotropin-releasing hormone (CRH), were specifically activated by

112 e stress-released neuropeptide corticotropin-releasing hormone (CRH), which influence the integrity o

113 have described the effects of corticotropin-releasing hormone (CRH), which is released from inflamed

114 , we have virally traced local corticotropin-releasing hormone (CRH)-expressing inhibitory interneuro

115 e genomes for genes resembling corticotropin-releasing hormone (CRH).

116 XT neurons that co-express the corticotropin-releasing hormone (CRH).

117 Furthermore, endogenous corticotropin-releasing hormone(+) (CRH(+)) LC inputs from the amygdal

118 of the pituitary changes from corticotropin-releasing hormone-dominant to arginine vasopressin-domin

119 bag cell neurons, which elicit ovulation by releasing hormones during an afterdischarge.

120 n addition, we discovered that corticotropin-releasing hormone-expressing cells contain GABAergic and

121 y dynorphin, somatostatin, and corticotropin-releasing hormone-expressing neurons in the CeA that pro

122 tance, resulting in increased corticotrophin-releasing hormone expression, chronic hypercortisolism,

123 The corticotropin-releasing hormone family mediates functional responses i

124 Neurons expressing the corticotropin-releasing hormone gene (Crh) in central amygdala (CeA) a

125 chum salmon (Oncorhynchus keta), thyrotropin-releasing hormone gene expression increased immediately

126 cultures using forskolin or a long-acting GH-releasing hormone (GHRH) analog increased GH production

127 Because growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) are

128 th inadequate compensation by Growth hormone-releasing hormone (GHRH) and Growth hormone (GH), undera

129 fects of agonistic analogs of growth hormone-releasing hormone (GHRH) and their mechanism of action w

130 Growth hormone-releasing hormone (GHRH) antagonist MIA-690 and GHRH ago

131 rong inhibitory activities of growth hormone-releasing hormone (GHRH) antagonists have been demonstra

132 inally, we also detected that growth hormone-releasing hormone (GHRH) antagonists, such as MIA602, ki

133 growth-stimulatory peptides, growth hormone-releasing hormone (GHRH) for GHRH-neurons and somatostat

134 Growth hormone-releasing hormone (GHRH) has been previously shown to ha

135 Agonists of growth hormone-releasing hormone (GHRH) have been previously reported t

136 act of targeted disruption of growth hormone-releasing hormone (GHRH) in mice on longevity and the pu

137 Growth hormone-releasing hormone (GHRH) is a hypothalamic neuropeptide

138 GH-releasing hormone (GHRH) neurons express estrogen recept

139 Hypothalamic growth hormone-releasing hormone (GHRH) neurons orchestrate body growth

140 MC), neuropeptide Y (NPY) and growth hormone releasing hormone (GHRH) neurons, regulates feeding, ene

141 It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomyocyte (CM) apop

142 The hypothalamic growth hormone-releasing hormone (GHRH) regulates the release of GH by

143 ion using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet viability and

144 in-releasing factor (CRF) and growth hormone-releasing hormone (GHRH), suggesting novel interactions

145 of the multiple activities of growth hormone-releasing hormone (GHRH), we hypothesized that pretreatm

146 ed by negative-feedback loops mediated by GH-releasing hormone (GHRH)- or somatostatin-expressing neu

147 nthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH or LHRH), is the active pharmace

148 Gonadotropin-releasing hormone (GnRH) agonists (e.g., triptorelin) ar

149 Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian fun

150 iandrogens (AA), 26,959 were on gonadotropin-releasing hormone (GnRH) agonists, and 3,747 underwent s

151 Women treated with gonadotropin-releasing hormone (GnRH) analogs may develop enteric neu

152 inasteride, spironolactone, and gonadotropin-releasing hormone (GnRH) analogs.

153 Both gonadotropin-releasing hormone (GnRH) and activins, members of the tr

154 te meiosis, TGF-beta signaling, gonadotropin-releasing hormone (GnRH) and epidermal growth factor rec

155 In vertebrates, gonadotropin-releasing hormone (GnRH) and gonadotropin-inhibitory hor

156 the synthesis and/or release of gonadotropin-releasing hormone (GnRH) and gonadotropins.

157 diol (E2) regulating release of gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH) ar

158 Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to

159 Dysfunction of the gonadotropin-releasing hormone (GnRH) axis causes a range of reproduc

160 puberty and infertility due to gonadotropin releasing hormone (GnRH) deficiency, which is often asso

161 Release of gonadotropin releasing hormone (GnRH) from the medial basal hypothala

162 with an inherited deficiency in gonadotropin-releasing hormone (GnRH) have impaired sexual reproducti

163 Gonadotropin-releasing hormone (GnRH) is a key regulator of reproduct

164 Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone sy

165 Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone th

166 Gonadotropin-releasing hormone (GnRH) is secreted in brief pulses fro

167 Gonadotropin-releasing hormone (GnRH) is secreted in brief pulses tha

168 The gonadotropin-releasing hormone (GnRH) is the master regulator of fert

169 The gonadotropin-releasing hormone (GnRH) is the master regulator of fert

170 atile, delivery of hypothalamic gonadotropin-releasing hormone (GnRH) leads to a marked decrease in s

171 We have previously shown that gonadotropin-releasing hormone (GnRH) ligand-independently activates

172 rons have been shown to inhibit gonadotropin-releasing hormone (GnRH) neuronal activity and hence rep

173 lases (HDACs) in the control of gonadotropin releasing hormone (GnRH) neuronal development is unknown

174 nfluence on the activity of the gonadotropin-releasing hormone (GnRH) neuronal network controlling fe

175 a key regulator of hypothalamic gonadotropin-releasing hormone (GnRH) neurons and is essential for re

176 Estradiol feedback regulates gonadotropin-releasing hormone (GnRH) neurons and subsequent luteiniz

177 oth the intrinsic properties of gonadotropin-releasing hormone (GnRH) neurons and synaptic inputs to

178 Gonadotropin-releasing hormone (GnRH) neurons are neuroendocrine cell

179 Gonadotropin-releasing hormone (GnRH) neurons are the final common pa

180 The gonadotropin-releasing hormone (GnRH) neurons are the key cells regul

181 Central output of gonadotropin-releasing hormone (GnRH) neurons controls fertility and

182 tioning in mammals depends upon gonadotropin-releasing hormone (GnRH) neurons generating a pulsatile

183 controlling the activity of the gonadotropin-releasing hormone (GnRH) neurons in vivo to establish th

184 ypogonadism to study effects of gonadotropin releasing hormone (GnRH) neurons on neuronal circuits co

185 Gonadotropin-releasing hormone (GnRH) neurons originate outside the C

186 Gonadotropin-releasing hormone (GnRH) neurons produce the central out

187 Gonadotropin-releasing hormone (GnRH) neurons regulate puberty onset

188 and electrophysiology, that the gonadotropin-releasing hormone (GnRH) neurons that control mammalian

189 radiol on proestrus to activate gonadotropin-releasing hormone (GnRH) neurons that, in turn, trigger

190 erminal Ca(2+) is controlled in gonadotropin-releasing hormone (GnRH) neurons via action potentials a

191 tes reproduction by stimulating gonadotropin-releasing hormone (GnRH) neurons via the kisspeptin rece

192 drive the pulsatile activity of gonadotropin-releasing hormone (GnRH) neurons.

193 ain regulates fertility through gonadotropin-releasing hormone (GnRH) neurons.

194 n by acting on gonadotropes and gonadotropin-releasing hormone (GnRH) neurons.

195 mal steroid hormone feedback to gonadotropin-releasing hormone (GnRH) neurons.

196 in cilia projecting from mouse gonadotropin-releasing hormone (GnRH) neurons.

197 nd depends upon the activity of gonadotropin-releasing hormone (GnRH) neurons.

198 ain regulates fertility through gonadotropin-releasing hormone (GnRH) neurons.

199 Hypothalamic gonadotropin-releasing hormone (GnRH) plays a critical role in reprod

200 eing.SIGNIFICANCE STATEMENT The gonadotropin-releasing hormone (GnRH) pulse generator controls the pu

201 ility critically depends on the gonadotropin-releasing hormone (GnRH) pulse generator, a neural const

202 The gonadotropin-releasing hormone (GnRH) receptor is a drug target for c

203 ure of information transfer via gonadotropin-releasing hormone (GnRH) receptors (GnRHR) to extracellu

204 lethargus, by signaling through gonadotropin-releasing hormone (GnRH) related receptors.

205 ity are associated with reduced gonadotropin-releasing hormone (GnRH) release and infertility.

206 of kisspeptin, which modulates gonadotropin-releasing hormone (GnRH) release from GnRH neurons to co

207 modulating the tonic pulsatile gonadotropin-releasing hormone (GnRH) release.

208 ion by brain-secreted pulses of gonadotropin-releasing hormone (GnRH) represents a longstanding puzzl

209 t MKRN3 is acting as a brake on gonadotropin-releasing hormone (GnRH) secretion during childhood.

210 hestrated by an augmentation of gonadotropin-releasing hormone (GnRH) secretion from a few thousand h

211 uisition of a mature pattern of gonadotropin-releasing hormone (GnRH) secretion from the CNS is a hal

212 Gonadotropin-releasing hormone (GnRH) secretion is regulated by estra

213 production as key regulators of gonadotropin-releasing hormone (GnRH) secretion.

214 Crz belongs to gonadotropin-releasing hormone (GnRH) superfamily, implying an analog

215 on ligands and receptors of the gonadotropin-releasing hormone (GnRH) superfamily.

216 e is an inherited deficiency of gonadotropin-releasing hormone (GnRH) that is characterized by hypogo

217 IKK-beta and NF-kappaB inhibit gonadotropin-releasing hormone (GnRH) to mediate ageing-related hypot

218 ropin hormones are regulated by gonadotropin-releasing hormone (GnRH) via MAPK signaling pathways tha

219 neurons that express genes for gonadotropin-releasing hormone (GnRH), a G-protein-coupled receptor f

220 express an antibody that binds gonadotropin-releasing hormone (GnRH), a master regulator of reproduc

221 hypothalamic neurons secreting gonadotropin-releasing hormone (GnRH), the neuropeptide controlling r

222 Gonadotropin-releasing hormone (GnRH)-expressing neurons migrate alon

223 secreting the 'master molecule' gonadotropin-releasing hormone (GnRH).

224 rease in pulsatile secretion of gonadotropin-releasing hormone (GnRH).

225 with regulation by activins and gonadotropin releasing hormone (GnRH).

226 duction in mammals by secreting gonadotropin-releasing hormone (GnRH).

227 n requires pulsatile release of gonadotropin-releasing hormone (GnRH1) from the hypothalamus.

228 he receptor of the neuropeptide gonadotropin-releasing hormone (GnRHR) is unique among the G protein-

229 type D with a fragment of the growth hormone releasing hormone, has previously revealed promising res

230 ex restrains the amygdala, the corticotropin-releasing hormone/hypothalamic-pituitary-adrenal (CRH/HP

231 de homologous to the vertebrate gonadotropin-releasing hormone, is downregulated as workers become ga

232 ated PTD showed higher CRP and corticotropin-releasing hormone levels.

233 (ACTH) and hypothalamic luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6]LHRH.

234 fied synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a targeting moiety specific

235 aclitaxel) conjugated to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and

236 were functionalized with Luteinizing Hormone-Releasing hormone (LHRH) ligands whose receptors are sho

237 able fragment (scFv) and luteinizing hormone releasing hormone (LHRH) peptide, resulting in specific

238 ortantly, SSA induced by luteinizing hormone-releasing hormone (LHRH) receptor antagonism bypassed th

239 Irradiation of luteinizing hormone releasing hormone (LHRH), growth hormone releasing hexap

240 maging in hormone-naive (luteinizing hormone-releasing hormone [LHRH] +/- bicalutamide) and in castra

241 ceived letrozole (plus a luteinizing hormone-releasing hormone [LHRH] agonist if premenopausal).

242 in or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and or

243 on mice, either with global or corticotropin-releasing hormone neuron-specific deletion, had impaired

244 in responses, suggesting normal gonadotropin-releasing hormone neuronal and gonadotrope function.

245 and send axonal projections to gonadotropin-releasing hormone neurons and regulate reproductive func

246 eus tractus solitarii (NTS) to corticotropin releasing hormone neurons in the paraventricular nucleus

247 ons relay estradiol feedback to gonadotropin-releasing hormone neurons, which regulate the reproducti

248 including direct innervation of gonadotropin releasing hormone neurons.

249 aging in the nerve terminals of gonadotropin-releasing hormone neurons.

250 membrane receptors but not by corticotropin-releasing hormone or dexamethasone.

251 these neurons largely express corticotrophin-releasing hormone or thyrotropin-releasing hormone and d

252 duction relies on hypothalamic gonadotrophin-releasing hormone output, and most cells producing repro

253 iology, specifically placental corticotropin-releasing hormone (pCRH).

254 on of stress-response receptor corticotropin-releasing hormone receptor (CRHR) in bladder from IC/BPS

255 ficial effects of agonists of growth hormone-releasing hormone receptor (GHRH-R) in heart failure mod

256 r (L-NAME) and stimulation of growth hormone-releasing hormone receptor (GHRHR) with GHRH agonists au

257 tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R).

258 Pharmacoperones of the gonadotropin releasing hormone receptor (GnRHR) have efficacy in cell

259 rtitioning mutant conformers of gonadotropin-releasing hormone receptor (GnRHR), a G protein-coupled

260 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negative modulation

261 -binding site defined--for the corticotropin-releasing hormone receptor 1 (CRF1R)--which was located

262 Corticotropin-releasing hormone receptor 1 (CRHR1) activates G protein

263 Variations in the corticotropin-releasing hormone receptor 1 (CRHR1) gene have been foun

264 In addition, GR and corticotropin-releasing hormone receptor 1 (CRHR1) genotypes contribut

265 ucocorticoid receptor [NR3C1], corticotropin-releasing hormone receptor 1 [CRHR1]) in isolated immune

266 ein 2)), chromosome 17 (CRHR1 (corticotropin-releasing hormone receptor 1) and MAPT (microtubule-asso

267 (p = 1.5 x 10(-12)), at CRHR1 (corticotropin-releasing hormone receptor 1); the protein product of th

268 rtin 2 (UCN2) and its receptor corticotropin-releasing hormone receptor 2 (CRHR2) are highly expresse

269 Activation of corticotropin-releasing hormone receptor 2 (CRHR2) in the colonic muco

270 eptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R] activity).

271 rescuing the activity of mutant gonadotropin-releasing hormone receptor or GnRHR which, is sequestere

272 ve ganglion cells (dsGCs): TRHR (thyrotropin-releasing hormone receptor) and Drd4 (dopamine receptor

273 mbrane progestin receptor, the corticotropin releasing hormone receptor, and the 5HT1a serotonin rece

274 icant three-way interaction on corticotropin-releasing hormone receptor-1 (Crhr1) gene expression, in

275 gold nanorods (gGNRs) promotes gonadotropin releasing hormone receptor-mediated internalization and

276 responses by binding to type 2 corticotropin-releasing hormone receptors.

277 , highlighting a role of SET in gonadotropin-releasing hormone regulation of gene expression.

278 s1 promoter disrupted pulsatile gonadotropin-releasing hormone release, delayed puberty and compromis

279 Gene expression of salmon gonadotropin-releasing hormone (sGnRH) and NR1 increased in the adult

280 itial and replication samples: corticotropin-releasing hormone signaling, cardiac beta-adrenergic sig

281 nalyses revealed enrichment of corticotropin-releasing hormone signaling, GNRH signaling, and/or CDK5

282 and is released in response to gonadotropin-releasing hormone, similar to LH.

283 Somatostatin, ghrelin, and GH-releasing hormones that regulate GH secretion from the a

284 eptors, and by the hypothalamic gonadotropin-releasing hormone through activation of PKA.

285 availability via leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormone expression

286 er factors control secretion of gonadotropin-releasing hormone to determine initiation of puberty.

287 satile, coordinated delivery of gonadotropin-releasing hormone to the pituitary and the resulting sur

288 5%, 35% and 63% of somatostatin, thyrotropin-releasing hormone (TRH) and corticotropin-releasing horm

289 om subsets of neurons expressing thyrotropin-releasing hormone (TRH) and pituitary adenylate cyclase-

290 yroid (HPT) axis hormones, i.e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH), are expre

291 loop that inhibits production of thyrotropin-releasing hormone (TRH) in the mediobasal hypothalamus (

292 In vertebrates thyrotropin-releasing hormone (TRH) is a highly conserved neuropepti

293 LepR are expressed mainly in thyrotropin-releasing hormone (TRH) neurons, some of which project t

294 phe-derived serotonin (5-HT) and thyrotropin-releasing hormone (TRH) play important roles in fundamen

295 Thyrotropin-releasing hormone (TRH) regulates the hypothalamic-pitui

296 Thyrotropin releasing hormone (TRH), a water soluble drug used for t

297 activated thyroid-stimulating hormone (TSH)-releasing hormone (TRH)-positive neurons in the paravent

298 , and do not express oxytocin, corticotropin-releasing hormone, vasopressin, or prodynorphin.

299 In the BPD mouse model, gonadotropin-releasing hormone was increased in females compared with

300 on requires timely secretion of gonadotropin-releasing hormone, which is controlled by a complex exci